Loading…
Loading…
EQUITY / NASDAQ · XNMS
Drugs Made In America Acquisition II Corp.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗10.18 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 10.18 USD · Volume 1,216
62 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -112,227 USD | -38,073 USD | — |
| Net income | 4,396,456 USD | -38,073 USD | — |
| Cash and cash equivalents | 174,974 USD | — | — |
| Total liabilities | 18,144,574 USD | — | — |
| Total equity | -17,926,751 USD | -214,119 USD | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 174,974 USD | — | — | 223 USD | 223 USD | — | — | — |
| Net incomeIncome statement | 4,396,456 USD | 8,734,276 USD | 4,337,820 USD | — | 4,187,050 USD | -46,158 USD | -143,558 USD | -38,073 USD |
| Operating profitIncome statement | -112,227 USD | -244,257 USD | — | — | -488,385 USD | -155,513 USD | -252,913 USD | -38,073 USD |
| Total assetsBalance sheet | 514,100,156 USD | — | — | 504,959,837 USD | 504,959,837 USD | 501,005,711 USD | — | — |
| Total equityBalance sheet | -17,926,751 USD | — | -17,814,524 USD | -17,774,827 USD | -17,774,827 USD | -17,280,989 USD | — | -214,119 USD |
| Total liabilitiesBalance sheet | 18,144,574 USD | — | — | 17,800,864 USD | 17,800,864 USD | 18,177,345 USD | — | — |
| Financing cash flowCash flow statement | — | 450,000 USD | — | — | 501,001,419 USD | — | 501,001,419 USD | — |
| Operating cash flowCash flow statement | — | -275,249 USD | — | — | -1,018,231 USD | — | -703,367 USD | — |
| Investing cash flowCash flow statement | — | — | — | — | -500,000,000 USD | — | -500,000,000 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 04/15/2026 | Open report ↗ Published: 11/18/2025 | Open report ↗ Published: 11/18/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.